Heart failure & cardiomyopathies

Iron Repletion in Heart Failure With Preserved Ejection Fraction: The IRONMET-HFpEF Randomized Trial

CirculationPublished double-blind, placebo-controlled randomized clinical trial

Primary result · Change in peak V̇O2 from baselineResult — go to the resultLeast-squares mean difference 1.1 mL·kg −1 ·min −1 95% CI 0.2–1.9

Authors' conclusion

In the largest trial to date of iron repletion in heart failure with preserved ejection fraction with iron deficiency, FDI improved multiple measures of exercise capacity.

Study context

Population
Patients with heart failure with preserved ejection fraction and iron deficiency, defined as ferritin <100 ng/mL or <300 ng/mL with transferrin saturation <20%randomized, 64 (98.5%) completed the study
Participants
65 patients
Comparison
Ferric derisomaltose compared with placebo
  • Ferric derisomaltose (FDI)n = 44
  • Placebon = 21
Primary endpoint
Change in peak V̇O2 from baseline
Follow-up
12 weeks

Primary result

Change in peak V̇O2 from baseline

Least-squares mean difference

1.1 mL·kg −1 ·min −1

95% CI 0.2–1.9

P = 0.02

Change by group

FDI

1.2

change (95% CI, 0.6-1.7) · mL·kg −1 ·min −1

Placebo

0.1

change (95% CI, −0.7 to 0.9) · mL·kg −1 ·min −1

FDIvs Placebo
least-squares mean difference 1.1 mL·kg −1 ·min −1 (95% CI 0.2–1.9); P = 0.02

As reported in the abstract

Secondary outcomes

OutcomeIncrease (95% CI)P value
Transferrin saturation · 12 weeks9.4% (4.9%–13.9%)P LSMD <0.001
OutcomeIncrease (ng/mL) (95% CI)P value
Ferritin · 12 weeks183 (128–238)P LSMD <0.001

Baseline peak V̇O2

V̇O2 at the anaerobic threshold, 6-minute walk test distance, New York Heart Association class · 12 weeks

Also improved in the FDI compared with the placebo group
all P <0.05

Kansas City Cardiomyopathy Questionnaire-Overall Summary Score · 12 weeks

Did not differ significantly between groups; FDI group
+4.4 [95% CI, −2.4 to 11.2]; P =0.20

Safety

No serious adverse events related to FDI administration

Original publication

Iron Repletion in Heart Failure With Preserved Ejection Fraction: The IRONMET-HFpEF Randomized Trial. Circulation. Published 8 November 2026. doi:10.1161/circulationaha.126.084009

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.